RESUMO
In 2005-2007, primary drug resistance of Mycobacterium tuberculosis (MBT) was studied in 1318 patients with new-onset destructive pulmonary tuberculosis. This was identified in 31.8, 28.5, and 29.1% in 2005, 2006, and 2007, respectively. During these years, there was an increase in the primary rifampicin resistance of MBT from 28.8% in 2005 to 37.7% in 2007. Primary streptomycin resistance was 100% in 2007. The authors consider the primary resistance of MBT as a priority problem of phthisiology.
Assuntos
Antituberculosos/uso terapêutico , Mycobacterium tuberculosis/efeitos dos fármacos , Tuberculose Resistente a Múltiplos Medicamentos/tratamento farmacológico , Tuberculose Pulmonar/tratamento farmacológico , Seguimentos , Humanos , Mycobacterium tuberculosis/isolamento & purificação , Prognóstico , Estudos Retrospectivos , Tuberculose Resistente a Múltiplos Medicamentos/microbiologia , Tuberculose Pulmonar/microbiologiaRESUMO
Of fundamental importance is the detection of tuberculosis among its higher risk population groups. This applies in full measure to medical students. The rates of Mycobacterium tuberculosis infection, its risk, tuberculin sensitivity, and incidence were studied in 2499 students from different higher educational establishments. During the study years, there was a significant increase in these parameters in medical students during study years as compared to humanitarian students, which allows medical students to be considered as an independent social tuberculosis-risk group.
Assuntos
Estudantes de Medicina , Tuberculose/epidemiologia , Adolescente , Adulto , Humanos , Incidência , Radiografia Torácica/métodos , Estudos Retrospectivos , Fatores de Risco , Federação Russa/epidemiologia , Teste Tuberculínico/métodos , Tuberculose/diagnósticoRESUMO
196 new cases of pulmonary tuberculosis are characterized. The patients' age ranged from 18 to 45. The majority were diagnosed late. The disease ran with marked intoxication and weight loss (5-20 kg), typical changes in the peripheral blood in 35.5% of patients, universal dysfunction of cellular and humoral immunity.